Ranibizumab and the Risk of Arterial Thromboembolic Events

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 380 participants.

Also called NCT01319188

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose screening
Phase
Phase 4
Enrolled
  • 380 participants (enrolled count) (from the registry)
Sponsor
Ural State Medical University (from the registry)
Registry
  • NCT NCT01319188
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Netherlands, Russia (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01319188. Randomized; double masking; primary purpose screening. Start 2010-06 (registry gives no type); primary completion 2012-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ranibizumab and the Risk of Arterial Thromboembolic Events
Acronym
RATE
Condition
Age-related Macular Degeneration
Condition
Cerebrovascular Disorders
Intervention (Drug)
0.5 mg of ranibizumab
Intervention (Procedure)
0.5 mg of ranibizumab + photodynamic therapy
Intervention (Other)
Sham injection
Lead sponsor
Ural State Medical University (class: other)
Collaborator
Ural Institute of Cardiology (class: other)
Collaborator
De Haar Research Foundation (class: other)

Record details

Record id
cardio:ct-nct01319188
Content hash
0430c278f7a13df2bbc591fbbd4ed5071bf51439f31d04c782647752bf3d4a74